Nuturna International marketed 'Diabetic Support Formula' with diabetes-treatment claims, making it an unapproved drug and misbranded.
What happened
In August 2021, FDA reviewed Nuturna's website and its Amazon storefront and product page. FDA found testimonials and claims that 'Diabetic Support Formula' lowers blood sugar and treats or prevents diabetes. FTC also reviewed the websites in August 2021 and demanded that the company stop making diabetes claims without competent and reliable scientific evidence.
What FDA found
The website and Amazon page claims and testimonials show the product is intended to treat, prevent, or mitigate diabetes, so it is a drug.
Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]The product is an unapproved new drug because it is not generally recognized as safe and effective for those uses and has no FDA approval.
Sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]The product is misbranded because it lacks adequate directions for safe use by a layperson for diseases that require a licensed practitioner.
Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 C.F.R. 201.5Introducing or delivering the misbranded drug into interstate commerce violates the Act.
Section 301(a) of the Act [21 U.S.C. 331(a)]FTC says the company must stop claiming a product can prevent, treat, or cure diabetes unless it has competent and reliable scientific evidence, including well-controlled human clinical studies.
FTC Act, 15 U.S.C. ยง 41 et seq.
What FDA wants
FDA asks Nuturna to notify it in writing within 15 working days of receipt of the specific steps taken to address the violations, including explanations and documentation; if corrective actions cannot be completed in that time, state why and when they will be done.
Who should pay attention
- dietary supplement brands making disease-related claims
- Amazon sellers and website marketers of supplements
- companies advertising diabetes or blood sugar products
This is a summary. Read the original letter on fda.gov.